- Home
- ACIC vs PCRX Comparison
ACIC vs PCRX Comparison
Compare ACIC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | PCRX |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | 829 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.4M | 1.0B |
| IPO Year | 2007 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ACIC | PCRX |
|---|---|---|
| Price | $9.27 | $25.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $30.25 |
| AVG Volume (30 Days) | 239.7K | ★ 439.2K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | 39.61 | ★ 107.44 |
| EPS | ★ 0.83 | 0.19 |
| Revenue | $335,439,000.00 | ★ $541,533,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | $1.00 | $8.54 |
| P/E Ratio | ★ $11.33 | $132.05 |
| Revenue Growth | 13.07 | ★ 26.04 |
| 52 Week Low | $9.03 | $18.80 |
| 52 Week High | $13.06 | $27.66 |
Technical Indicators
Market Signals| Indicator | ACIC | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 51.13 |
| Support Level | $9.10 | $24.61 |
| Resistance Level | $9.68 | $27.03 |
| Average True Range (ATR) | 0.19 | 0.86 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 54.26 | 66.52 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.